Interleukin-33 in human gliomas: Expression and prognostic significance

Oncology Letters

Volumn 12, Issue 1, 2016, Pages 445-452

  Gramatzki, Dorothee ^a   Frei, Karl ^b   Cathomas, Gieri ^c   Moch, Holger ^b   Weller, Michael ^a,d   Mertz, Kirsten Diana ^b,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Kantonsspital Liestal   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Glioma; Interleukin 1 receptor accessory protein; Interleukin 1 receptor like 1 protein; Interleukin 33; Survival; Tissue microarray

Indexed keywords

BEVACIZUMAB; GEFITINIB; INTERLEUKIN 1; INTERLEUKIN 33; IRINOTECAN; LOMUSTINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR LOCALIZATION;

EID: 84973468842     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4626     Document Type: Article

References (48)

1. Gramatzki D, Dehler S, Rushing EJ, Zaugg K, Hofer S, Yonekawa Y, Bertalanffy H, Valavanis A, Korol D, Rohrmann S, et al: Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer: Apr 18, 2016 (Epub ahead of print).
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
3. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, et al: EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15: e395-e403, 2014.
4. Huse JT and Holland EC: Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10: 319-331, 2010.
5. Charles NA, Holland EC, Gilbertson R, Glass R and Kettenmann H: The brain tumor microenvironment. Glia 59: 1169-1180, 2011.
6. Lin Y, Zhang G, Zhang J, Gao G, Li M, Chen Y, Wang J, Li G, Song SW, Qiu X, et al: A panel of four cytokines predicts the prognosis of patients with malignant gliomas. J Neurooncol 114: 199-208, 2013.
7. Prosniak M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbaeva K, Apanasovich TV, Heber-Katz E, Curtis MT, Cotzia P and Hooper DC: Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res 19: 3776-3786, 2013.
8. Yeung YT, McDonald KL, Grewal T and Munoz L: Interleukins in glioblastoma pathophysiology: Implications for therapy. Br J Pharmacol 168: 591-606, 2013.
9. Zhu VF, Yang J, Lebrun DG and Li M: Understanding the role of cytokines in glioblastoma multiforme pathogenesis. Cancer Lett 316: 139-150, 2012.
10. Schiering C, Krausgruber T, Chomka A, Fröhlich A, Adelmann K, Wohlfert EA, Pott J, Griseri T, Bollrath J, Hegazy AN, et al: The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513: 564-568, 2014.
11. Beltrán CJ, Núñez LE, Díaz-Jiménez D, Farfan N, Candia E, Heine C, López F, González MJ, Quera R and Hermoso MA: Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 16: 1097-1107, 2010.
12. Palmer G and Gabay C: Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 7: 321-329, 2011.
13. Préfontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, Martin JG and Hamid Q: Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 125: 752-754, 2010.
14. Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X, Wu K, You Y, Alevy Y, Girard JP, et al: Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest 123: 3967-3982, 2013.
15. Kempf W, Zollinger T, Sachs M, Ullmer E, Cathomas G, Dirnhofer S and Mertz KD: Granulomas are a source of interleukin-33 expression in pulmonary and extrapulmonary sarcoidosis. Hum Pathol 45: 2202-2210, 2014.
16. Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G and Gabay C: Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40: 216-225, 2007.
17. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et al: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490, 2005.
18. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S and Kastelein RA: IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179: 2551-2555, 2007.
19. Küchler AM, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen DR, De Angelis PM, Scott H and Haraldsen G: Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 173: 1229-1242, 2008.
20. Moussion C, Ortega N and Girard JP: The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel 'alarmin'? PLoS One 3: e3331, 2008.
21. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G and Girard JP: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104: 282-287, 2007.
22. Alves-Filho JC, Sônego F, Souto FO, Freitas A, Verri WA Jr, Auxiliadora-Martins M, Basile-Filho A, McKenzie AN, Xu D, Cunha FQ and Liew FY: Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 16: 708-712, 2010.
23. Haraldsen G, Balogh J, Pollheimer J, Sponheim J and Küchler AM: Interleukin-33-cytokine of dual function or novel alarmin? Trends Immunol 30: 227-233, 2009.
24. Roussel L, Erard M, Cayrol C and Girard JP: Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 9: 1006-1012, 2008.
25. Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S and Zaheer A: Alzheimer's disease: Evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis 40: 297-308, 2014.
26. Christophi GP, Gruber RC, Panos M, Christophi RL, Jubelt B and Massa PT: Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol 142: 308-319, 2012.
27. Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M, Sonobe Y, Takeuchi H, Mizuno T and Suzumura A: Production and functions of IL-33 in the central nervous system. Brain Res 1385: 8-17, 2011.
28. Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA and Massa PT: Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 84: 631-643, 2008.
29. Han P, Mi WL and Wang YQ: Research progress on interleukin-33 and its roles in the central nervous system. Neurosci Bull 27: 351-357, 2011.
30. Kempuraj D, Khan MM, Thangavel R, Xiong Z, Yang E and Zaheer A: Glia maturation factor induces interleukin-33 release from astrocytes: Implications for neurodegenerative diseases. J Neuroimmune Pharmacol 8: 643-650, 2013.
31. Sun P, Ben Q, Tu S, Dong W, Qi X and Wu Y: Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 56: 3596-3601, 2011.
32. Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O and Radeke HH: High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol 6: 311-318, 2013.
33. Hu LA, Fu Y, Zhang DN and Zhang J: Serum IL-33 as a diagnostic and prognostic marker in non-small cell lung cancer. Asian Pac J Cancer Prev 14: 2563-2566, 2013.
34. Fang KM, Yang CS, Lin TC, Chan TC and Tzeng SF: Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells. Neuro Oncol 16: 552-566, 2014.
35. Louis DN, Ohgaki H, Wiestler B and Cavenee WK (eds): WHO Classification of Tumours of the Central Nervous System. IARC Press, Lyon, 2007.
36. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.
37. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, et al: Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69: 9065-9072, 2009.
38. Singhal G, Jaehne EJ, Corrigan F, Toben C and Baune BT: Inflammasomes in neuroinflammation and changes in brain function: A focused review. Front Neurosci 8: 315, 2014.
39. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Arsenijevic NN and Lukic ML: IL-33/ST2 axis in innate and acquired immunity to tumors. Oncoimmunology 1: 229-231, 2012.
40. Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP and Weiner DB: Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 74: 1789-1800, 2014.
41. Gao K, Li X, Zhang L, Bai L, Dong W, Gao K, Shi G, Xia X, Wu L and Zhang L: Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett 335: 463-471, 2013.
42. Curran CS and Bertics PJ: Eosinophils in glioblastoma biology. J Neuroinflammation 9: 11, 2012.
43. Hussain SF, Yang D, Suki D, Aldape K, Grimm E and Heimberger AB: The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 8: 261-279, 2006.
44. Dong H, Zhang X and Qian Y: Mast cells and neuroinflammation. Med Sci Monit Basic Res 20: 200-206, 2014.
45. Skaper SD, Facci L and Giusti P: Mast cells, glia and neuroinflammation: Partners in crime? Immunology 141: 314-327, 2014.
46. Merk BC, Owens JL, Lopes MB, Silva CM and Hussaini IM: STAT6 expression in glioblastoma promotes invasive growth. BMC Cancer 11: 184, 2011.
47. Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, Kim J, Kim YM and Kwon YG: Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 114: 3117-3126, 2009.
48. Gadani SP, Walsh JT, Smirnov I, Zheng J and Kipnis J: The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron 85: 703-709, 2015.